Co-Authors
This is a "connection" page, showing publications co-authored by Michael Liptay and Gary Chmielewski.
Connection Strength
0.507
-
Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Lung. 2019 06; 197(3):327-332.
Score: 0.159
-
Understanding barriers to lung cancer screening in primary care. J Thorac Dis. 2020 May; 12(5):2536-2544.
Score: 0.043
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.036
-
Durability of Silicone Airway Stents in the Management of Benign Central Airway Obstruction. Lung. 2017 10; 195(5):601-606.
Score: 0.035
-
Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. Lung. 2016 08; 194(4):619-24.
Score: 0.032
-
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
Score: 0.032
-
Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
Score: 0.031
-
Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
Score: 0.031
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.029
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
Score: 0.029
-
Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
Score: 0.026
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.025